Relevant bibliographies by topics / Pharmacology of antidepressants / Books
To see the other types of publications on this topic, follow the link: Pharmacology of antidepressants.

Books on the topic 'Pharmacology of antidepressants'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Pharmacology of antidepressants.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Stahl, S. M. Antidepressants. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stahl, S. M. Antidepressants. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Antidepressants: Pharmacology, health effects and controversy. New York: Nova Science Publishers, Inc., 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Leonard, B. E. Differential effects of antidepressants. London: Martin Dunitz, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Psych, Healy David MRC, ed. Differential effects of antidepressants. London: Martin Dunitz, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Giorgio, Racagni, and Brunello Nicoletta, eds. Critical issues in the treatment of affective disorders. Basel: Karger, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bennett, Shoshana S. Pregnant on Prozac: The essential guide to making the best decision for you and your baby. Guilford, Conn: GPP Life, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Quality, United States Agency for Healthcare Research and. Second-generation antidepressants in the pharmacologic treatment of adult depression: An update of the 2007 comparative effectiveness review : executive Summary. Rockville, Md: Agency for Healthcare Research and Quality, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stahl, S. M. Stahl's essential psychopharmacology: The prescriber's guide. Edited by Stahl, S. M. the prescriber's guide. and Stahl, S. M. the prescriber's guide. 3rd ed. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stahl, S. M. the prescriber's guide. and Stahl, S. M. the prescriber's guide., eds. Stahl's essential psychopharmacology: The prescriber's guide. 3rd ed. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

M, Stahl S., ed. Stahl's essential psychopharmacology: The prescriber's guide. 3rd ed. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Essential psychopharmacology: The prescriber's guide. Cambridge [England]: Cambridge University Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Essential psychopharmacology: Neuroscientific basis and clinical applications. Cambridge: Cambridge University Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Stahl, S. M. Essential psychopharmacology: Neuroscientific basis and clinical applications. Cambridge: Cambridge University Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Thakore, L. Handbook of Pharmacology of Antidepressants. Science Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Antidepressants. Basel: Birkhäuser Verlag, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Monroe, Judy. Antidepressants (Drug Library). Tandem Library, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Antidepressants (Drug Library). Enslow Publishers, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

J, Mendlewicz, Brunello Nicoletta, and Judd Lewis L, eds. New therapeutic indications of antidepressants. Basel: Karger, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Ruth, Porter, Bock Gregory, Clark Sarah, Ciba Foundation, and Symposium on Depression, Antidepressants, and Receptor Sensitivity (1985 : Ciba Foundation), eds. Antidepressants and receptor function. Chichester: Wiley, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

E, File S., ed. Psychopharmacology of anxiolytics and antidepressants. New York: Pergamon, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

E, File Sandra, ed. Psychopharmacology of anxiolytics and antidepressants. New York: Pergamon Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Nobles, Ryan. Pharmacology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190217518.003.0008.

Full text
Abstract:
This chapter focuses on principles of pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, and common indications with regard to opioids, nonsteroidal anti-inflammatory agents, acetaminophen, anticonvulsants, and antidepressants. The questions are formulated to focus on the most relevant topics that may be tested on the listed medications, but it is not a comprehensive review. The information provided should be supplemented with additional study of the cited literature in the Further Reading section for each question.
APA, Harvard, Vancouver, ISO, and other styles
24

(Editor), Sheldon H. Preskorn, Christina Y. Stanga (Editor), John P. Feighner (Editor), and Ruth Ross (Editor), eds. Antidepressants: Past, Present and Future (Handbook of Experimental Pharmacology). Springer, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Antidepressants (Milestones in Drug Therapy). Birkhauser, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

(Editor), Helmut Buschmann, Jörg Holenz (Editor), Antonio Párraga (Editor), Antoni Torrens (Editor), José Miguel Vela (Editor), and José Luis Díaz (Editor), eds. Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Wiley-VCH, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Leonard, Brian E., and David Healy. Differential Effects of Antidepressants. Informa Healthcare, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

M, Briley, and Montgomery S. A, eds. Antidepressant therapy at the dawn of the third millennium. St. Louis: Mosby, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Stahl, Stephen M. Essential Psychopharmacology: the Prescriber's Guide: Antidepressants (Essential Psychopharmacology Series). Cambridge University Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Stahl's Essential Psychopharmacology - Prescriber's Guide. University of Cambridge ESOL Examinations, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Harrison, Mark. Central nervous system. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198765875.003.0041.

Full text
Abstract:
This chapter describes the pharmacology of the central nervous system as it applies to Emergency Medicine, and in particular the Primary FRCEM examination. The chapter outlines the key details of hypnotics and anxiolytics, antipsychotics, antimania drugs, tricyclic antidepressants, nausea and vomiting, analgesics, non-opioid analgesics, opioid analgesics, antiepileptics, and status epilepticus. This chapter is laid out exactly following the RCEM syllabus, to allow easy reference and consolidation of learning.
APA, Harvard, Vancouver, ISO, and other styles
32

1941-, Gastpar M., and Wakelin J. S, eds. Selective 5-HT reuptake inhibitors: Novel or commonplace agents? Basel: Karger, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Gastpar, M. Selective 5-Ht Reuptake Inhibitors: Novel or Commonplace Agents? (Advances in Biological Psychiatry). S. Karger Publishers (USA), 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

(Editor), Husseini K. Manji, Charles L. Bowden (Editor), and Robert H., M.D. Belmaker (Editor), eds. Bipolar Medications: Mechanisms of Action. American Psychiatric Publishing, Inc., 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Bipolar medications : mechanisms of action. Washington, DC: American Psychiatric Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

(Editor), Erminio Costa, ed. Gaba Receptors and Anxiety: From Neurobiology to Treatment (Advances in Biochemical Psychopharmacology). Raven Pr, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Jolly, Elaine, Andrew Fry, and Afzal Chaudhry, eds. Clinical pharmacology and therapeutics. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199230457.003.0005.

Full text
Abstract:
Chapter 5 covers the basic science and clinical topics relating to clinical pharmacology and therapeutics which trainees are required to learn as part of their basic training and demonstrate in the MRCP. It covers pharmacodynamics, pharmacokinetics, drug metabolism and prescribing in special circumstances, drug interactions, adverse drug reactions, drug development, paracetamol poisoning, salicylate poisoning, lithium toxicity, digoxin toxicity, carbon monoxide poisoning, ethylene glycol poisoning, and tricyclic antidepressant poisoning.
APA, Harvard, Vancouver, ISO, and other styles
38

Tolin, David F., and Blaise L. Worden. Combining Pharmacotherapy and Psychological Treatments for OCD. Edited by Gail Steketee. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195376210.013.0081.

Full text
Abstract:
This chapter reviews the outcome literature on the efficacy of combined pharmacotherapy and cognitive-behavioral therapy (CBT) for obsessive compulsive disorder (OCD). By far, most research on combinations of CBT and pharmacotherapy for OCD has examined antidepressant medications, particularly those in the serotonin reuptake inhibitor (SRI) class. Quantitative review of randomized studies in which treatments were combined simultaneously indicated that combined therapy shows a small but significant advantage over exposure and response prevention (ERP) monotherapy, and a moderate advantage over pharmacologic (antidepressant) monotherapy. Studies of sequential treatment combination, in which CBT was added after a trial of antidepressant medication, suggest a significant incremental benefit of CBT, including for patients who show minimal response to antidepressant medication alone. The chapter concludes by discussing new pharmacologic possibilities for combined therapy, such as the use of D-cycloserine (DCS).
APA, Harvard, Vancouver, ISO, and other styles
39

Tolin, David F., and Blaise L. Worden. Combining Pharmacotherapy and Psychological Treatments for OCD. Edited by Gail Steketee. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195376210.013.019_update_001.

Full text
Abstract:
This chapter reviews the outcome literature on the efficacy of combined pharmacotherapy and cognitive-behavioral therapy (CBT) for obsessive compulsive disorder (OCD). By far, most research on combinations of CBT and pharmacotherapy for OCD has examined antidepressant medications, particularly those in the serotonin reuptake inhibitor (SRI) class. Quantitative review of randomized studies in which treatments were combined simultaneously indicated that combined therapy shows a small but significant advantage over exposure and response prevention (ERP) monotherapy, and a moderate advantage over pharmacologic (antidepressant) monotherapy. Studies of sequential treatment combination, in which CBT was added after a trial of antidepressant medication, suggest a significant incremental benefit of CBT, including for patients who show minimal response to antidepressant medication alone. The chapter concludes by discussing new pharmacologic possibilities for combined therapy, such as the use of D-cycloserine (DCS).
APA, Harvard, Vancouver, ISO, and other styles
40

1960-, Ozawa H., Saito Toshikazu, Takahata Naohiko 1932-, Nihon Seishin Shinkei Gakkai, and Symposium on Affective Disorders and Neuronal Signal Transduction (1996 : Sapporo-shi, Japan), eds. Signal transduction in affective disorders. Tokyo: Springer, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

Jani, Suni, Ryan Herringa, and Derek Hursey. Pharmacologic Treatment of Children with Trauma- and Stressor-Related Disorders. Edited by Frederick J. Stoddard, David M. Benedek, Mohammed R. Milad, and Robert J. Ursano. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190457136.003.0023.

Full text
Abstract:
This chapter reviews the principles of psychopharmacological treatment for trauma and stressor-related disorders in children. It will discuss emerging psychopharmacological treatments and theories of trauma- and stress-related disorders (TSRDs) common to childhood, reactive attachment disorder, and disinhibited social engagement disorder. Although there is limited literature on the role of pharmacotherapy in treating TSRDs in children, it has been recognized that α‎- and β‎-adrenergic blocking agents, novel antipsychotic agents, non-selective serotonin reuptake inhibitor antidepressants such as tricyclic antidepressants, and mood-stabilizing agents may be effective for children based on several open clinical trials. These trials, as well as existing promising clinical trials, are discussed in this chapter. It also provides an in-depth review of factors such as potential side effects, medication interactions, and black box warnings as they specifically apply to the pediatric population.
APA, Harvard, Vancouver, ISO, and other styles
42

Nestler, Eric J. New Approaches for Treating Depression. Edited by Dennis S. Charney, Eric J. Nestler, Pamela Sklar, and Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0030.

Full text
Abstract:
Several obstacles have impeded the introduction of new antidepressant medications over the past six decades. These obstacles include our still rudimentary knowledge of the biological basis of depression, as well as difficulties in evaluating the therapeutic efficacy of new putative antidepressant mechanisms in pathophysiologically distinct subtypes of the syndrome. Despite these obstacles, several tangible steps can be taken to advance depression treatment moving forward. The field needs to continue to take advantage of serendipitous discoveries in humans, such as the demonstration of rapid antidepressant effects of ketamine. Re-establishing experimental pharmacology in humans, to make it possible to establish the actions of new mechanisms in people, is essential, combined with the judicious use of a growing range of chronic stress models in animals. We anticipate that, with these approaches, the field can at long last breakthrough the logjam of discovery and introduce new treatments for depression over the next decade.
APA, Harvard, Vancouver, ISO, and other styles
43

Venuto, Charles S., and Karl Kieburtz. Huntington Disease. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0008.

Full text
Abstract:
The clinical management of Huntington’s disease entails pharmacologic interventions and nonpharmacologic supportive therapy. There are no treatments that can halt or alter the progression of disease, therefore the goal is to maximize function and optimize quality of life. Tetrabenazine is the only pharmacologic agent with regulatory approval for Huntington’s disease chorea; however, off-label use of antidopaminergic agents is common. Treatment of behavioral disturbances can be tailored to the specific symptoms by using antidepressant, antipsychotic, and anxiolytic agents. Clinical trials testing therapeutic strategies for motor, behavioral, and cognitive aspects of disease and delaying progression are ongoing.
APA, Harvard, Vancouver, ISO, and other styles
44

Hendrickson, Rebecca C., and Murray A. Raskind. Pharmacological Treatment of Nightmares, Sleep Disturbance, and Daytime Hyperarousal in PTSD: The Role of Prazosin, Other Noradrenergic Modulators, and Sedative Hypnotics or Commonly Used Sedating Medications. Edited by Charles B. Nemeroff and Charles R. Marmar. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190259440.003.0035.

Full text
Abstract:
Disruption of stress-response systems contributes to the pathophysiology of post-traumatic stress disorder (PTSD). Consistent with this, daytime hyperarousal and nighttime sleep disruption, including trauma-related nightmares, are core symptoms of the disorder, often requiring targeted pharmacologic treatment. Although a variety of medications that target sleep–wake and arousal mechanisms are commonly used for this purpose, there remains the best empirical support for prazosin, a brain-active antagonist of the α‎1 noradrenaline receptor, with emerging evidence for doxazosin, a longer-acting medication with the same mechanism of action. This chapter reviews the evidence for use of prazosin and doxazosin as well as for the sedative hypnotics (benzodiazepines, nonbenzodiazepine hypnotics, and related medications), antihistamines, and sedating antidepressants trazodone and nefazodone to address hyperarousal symptoms and trauma-associated nightmares in PTSD. Clinical recommendations for the use of prazosin in PTSD, as well as a discussion of emerging pharmacologic treatments, are also included.
APA, Harvard, Vancouver, ISO, and other styles
45

Elger, Bernice S. Management of sleep complaints in correctional settings. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199360574.003.0016.

Full text
Abstract:
Inmates of correctional settings often seek health care for sleep and drug problems. Studies on insomnia in correctional institutions are scarce. Sleep problems among detainees are frequent. Appropriate evaluation and treatment remains a challenge in correctional settings. Correctional health professionals need appropriate education regarding insomnia evaluation and management. Guidelines should be based on the principle of equivalence of care and take into account all evidence from research in the community and in correctional settings. Priority should be given to assessing modifiable causes and contributions to disturbed sleep and to non-pharmacological treatment such as targeted cognitive behavior therapy. Pharmacologically, there is no evidence-based justification to replace short-term pharmacologic management using benzodiazepines with antipsychotics or antidepressants. In correctional settings, prescriptions of antipsychotics and antidepressants for sleep problems can increase risk due to polypharmacy and higher suicide risks. Correctional physicians should monitor and document the evaluation and treatment practice concerning insomnia complaints in order to improve safe, evidence-based treatment. This chapter outlines treatment guidelines for insomnia that apply in community settings and then presents an overview of the clinical and ethical issues of insomnia management in correctional institutions and provides evidence-based recommendations.
APA, Harvard, Vancouver, ISO, and other styles
46

Krystal, John H., and Dennis S. Charney. Current Treatments for Depression. Edited by Dennis S. Charney, Eric J. Nestler, Pamela Sklar, and Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0031.

Full text
Abstract:
Depression is among the most common and disabling medical disorders worldwide. Pharmacotherapy plays an important role in its treatment, although only half of all depressed patients show full remission with currently available therapies. This chapter reviews the most common pharmacotherapies with respect to their mechanisms of action, efficacy, tolerability, and safety. It also considers pharmacologic approaches to treatment-resistant symptoms of depression including adjunctive pharmacotherapies and the emerging rapid-acting antidepressants. An important focus of current research is to devise biological measures that direct a given patient to an effective form of treatment. Depression research is at a very exciting phase that will have important consequences for affected patients and for society overall.
APA, Harvard, Vancouver, ISO, and other styles
47

Kramer, Peter D. Listening to Prozac: A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self. Penguin (Non-Classics), 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
48

Kramer, Peter D. Listening to Prozac: A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self. Penguin (Non-Classics), 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Listening to Prozac : A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self. DIANE Publishing Company, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Absalom, Anthony, and John Sear. Intravenous anaesthetics. Edited by Michel M. R. F. Struys. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199642045.003.0015.

Full text
Abstract:
In recent decades, increasing attention has been focused on the intravenous anaesthetic agents. This interest has been stimulated by the discovery and availability of agents with increasingly favourable pharmacokinetic and dynamic properties, coupled with advances in knowledge of pharmacology and advances in computer technology. For most patients and operative procedures, anaesthesia is induced with a bolus or fast infusion of a short-acting drug, most commonly propofol. Increasingly, anaesthesia is thereafter also maintained with an infusion of an agent with favourable kinetics, again usually of propofol, commonly supplemented with boluses or infusions of opioids. Propofol is also commonly used for procedural and intensive care sedation. It has highly favourable pharmacokinetics and pharmacodynamics for these applications as sedative or hypnotic agent—rapid, smooth onset, minimal accumulation, and rapid smooth offset of effect—but is by no means an ideal agent. In some specific situations, such as when its haemodynamic or respiratory effects are detrimental, use of alternative agents such as ketamine and etomidate are warranted. All the currently available agents have adverse effects, some of which are related to the active compound and some of which are related to the vehicle. Efforts are thus being made to develop new formulations, with fewer adverse effects, and to develop newer and better drugs. In the future we are also likely to see increasing use of older agents, but for newer indications (such as the use of ketamine as an antidepressant).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Pharmacology of antidepressants' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography